Headlands Technologies LLC Purchases New Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Headlands Technologies LLC acquired a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 3,183 shares of the company's stock, valued at approximately $1,057,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Proficio Capital Partners LLC boosted its holdings in shares of Medpace by 34,497.4% during the fourth quarter. Proficio Capital Partners LLC now owns 242,528 shares of the company's stock worth $80,575,000 after purchasing an additional 241,827 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Medpace in the 4th quarter valued at approximately $78,144,000. Norges Bank acquired a new position in shares of Medpace during the 4th quarter worth $69,859,000. Iron Triangle Partners LP acquired a new position in Medpace during the third quarter worth $64,371,000. Finally, GW&K Investment Management LLC increased its holdings in shares of Medpace by 93.9% during the 4th quarter. GW&K Investment Management LLC now owns 275,460 shares of the company's stock valued at $91,516,000 after acquiring an additional 133,379 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Medpace Price Performance

Shares of MEDP traded down $17.00 during trading hours on Friday, hitting $287.11. The stock had a trading volume of 833,195 shares, compared to its average volume of 307,847. The stock has a market capitalization of $8.75 billion, a price-to-earnings ratio of 22.73, a P/E/G ratio of 3.81 and a beta of 1.45. The company's fifty day moving average is $331.56 and its two-hundred day moving average is $337.49. Medpace Holdings, Inc. has a 52 week low of $282.42 and a 52 week high of $459.77.

Remove Ads

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Equities analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analysts Set New Price Targets

MEDP has been the subject of a number of research analyst reports. Leerink Partners assumed coverage on shares of Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 target price for the company. Leerink Partnrs raised shares of Medpace to a "hold" rating in a research report on Monday, March 24th. Finally, Robert W. Baird lifted their target price on Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a research report on Monday, January 27th. Nine investment analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, Medpace currently has a consensus rating of "Hold" and an average price target of $376.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.